Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5136MR)

This product GTTS-WQ5136MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_001167928.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3556
UniProt ID	Q9NPH3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5136MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4567MR	IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	BMS-936564
GTTS-WQ1792MR	IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ADCT-402
GTTS-WQ13462MR	IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	PRS-343
GTTS-WQ14812MR	IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	SGN-70
GTTS-WQ1216MR	IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	ABR-217620
GTTS-WQ930MR	IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ABBV-321
GTTS-WQ15307MR	IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	TNFR55-Ig1
GTTS-WQ14628MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST